Systematic sampling during MRI-US fusion prostate biopsy can overcome errors of targeting-prospective single center experience after 300 cases in first biopsy setting

• Published in: Translational andrology and urology 2020-12, Vol.9 (6), p.2510-2518
• Main Authors: Cata, Emanuel, Andras, Iulia, Ferro, Matteo, Kadula, Pierre, Leucuta, Daniel, Musi, Gennaro, Matei, Deliu-Victor, De Cobelli, Ottavio, Tamas-Szora, Attila, Caraiani, Cosmin, Lebovici, Andrei, Epure, Flavia, Bungardean, Maria, Coman, Radu-Tudor, Crisan, Nicolae
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 2223-4691; 2223-4683; 2223-4691
• DOI: 10.21037/tau-20-1001

Multiparametric magnetic resonance imaging (mpMRI) and targeted biopsy have become an integral part of the diagnosis of prostate cancer (PCa), as recommended by the European Association of Urology Guidelines. The aim of the current study was to evaluate the performance of MRI and MRI-transrectal ultrasound (TRUS) fusion prostate biopsy as first biopsy setting in a tertiary center. A cohort of 300 patients was included in the current analysis. All patients presented with clinical or biochemical suspicion of PCa and harbored at least one suspect lesion on mpMRI. MRI-TRUS fusion prostate biopsy, followed by 12 core systematic prostate biopsy were performed by the same operator using a rigid registration system. The mean age of the patients was 64 years (IQR: 58-68.5 years) and the mean PSA was 6.35 ng/mL (IQR: 4.84-9.46 ng/mL). Overall cancer and csPCa diagnosis rates were 47% and 40.66%. Overall PCa/csPCa detection rates were 20.4%/11.1%, 52%/45% and 68.5%/66.7% for PI-RADS lesions 3, 4 and 5 (P